CDK9-IN-36
CDK9-IN-36 (Compound T7) is a potent, selective and metabolically stable CDK9 inhibitor with an IC50 value of 1.2 nM. CDK9-IN-36 effectively suppresses cell proliferation, reduces colony formation, and induces apoptosis in Osimertinib -resistant NSCLC cells by downregulating Mcl-1. CDK9-IN-36 also demonstrates antitumor efficacy in a tumor xenograft model[1].
Product Specifications
UNSPSC
12352005
Target
Apoptosis; CDK
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
FC1=C(C2=CC(OCCCCCCO3)=C(C=C2)F)N=C(NC4=CC=C(C(NC5CCN(C(C)=O)CC5)=O)C3=C4)N=C1
Molecular Formula
C30H33F2N5O4
Molecular Weight
565.61
References & Citations
[1]Wu T, et al. Rational Design of a Potent, Selective, and Metabolically Stable CDK9 Inhibitor to Counteract Osimertinib Resistance through Mcl-1 Suppression and Enhanced BRD4 Co-Targeting. J Med Chem. 2025 Feb 27;68 (4) :4929-4950.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK9
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
CSB-EP614901HU-01 10 µg
Recombinant Human Neuronal pentraxin-1 (NPTX1), partial
Sign In for Pricing
View Details CSB-EP614901HU-02 50 µg
Recombinant Human Neuronal pentraxin-1 (NPTX1), partial
Sign In for Pricing
View Details CSB-EP614901HU-03 200 µg
Recombinant Human Neuronal pentraxin-1 (NPTX1), partial
Sign In for Pricing
View Details CSB-EP614901HU-04 500 µg
Recombinant Human Neuronal pentraxin-1 (NPTX1), partial
Sign In for Pricing
View Details